GEN Exclusives

More »

GEN News Highlights

More »
Mar 9, 2007

Innogenetics’ Permanent Injunction Against Abbott Upheld

  • The U.S. Court of Appeals denied Abbott Laboratories' motion for a stay of injunction in favor of Innogenetics regarding the willful infringement of Innogenetics patented hepatitis C virus genotyping technology.

    A January 10, 2007 ruling by the U.S. District Court for the Western District of Wisconsin permanently prevented Abbott from any further sales, use, or export of products that infringe on Innogenetics' patent and awarded $7 million in damages. Abbott then filed an emergency motion to stay the injunction pending its appeal. On January 19, the Federal Circuit temporarily stayed the injunction while it considered Abbott's motion.

    "Yesterday's decision marks a positive first step in the appeal process and reinforces our belief that we will prevail in the Court of Appeals, just as we did at trial," says Frank Morich, CEO of Innogenetics.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »